Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05124275 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
A Phase 2 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT05124275: Completed Phase 2 study, sponsored by Glaukos Corporation.
NCT05124275 is a Phase 2 study that has completed, run by Glaukos Corporation. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05124275, a Phase 2 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.
Primary Outcome
Proportion of treatment responders \[subjects gaining 3 lines or more in binocular distance corrected near visual acuity (DCNVA) and not losing more than 5 letters of binocular best corrected distance visual acuity (BCDVA)\] 1 hour post-dose at the Day 28 visit.
Interventions
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 1
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 2
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 3
- DRUG Placebo Ophthalmic Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
What the finished NCT05124275 record still lists
NCT05124275 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Pilocarpine Ophthalmic Topical Cream, Dose 1 is the first listed.
NCT05124275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05124275 about?
NCT05124275 is a clinical study titled "Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia". This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.
What is the current status of trial NCT05124275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2022-01-03. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT05124275?
The interventions under investigation include: Pilocarpine Ophthalmic Topical Cream, Dose 1 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 2 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 3 (DRUG), Placebo Ophthalmic Topical Cream (DRUG).
Who is sponsoring clinical trial NCT05124275?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05124275's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI